This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.
OVERVIEW OF ACTIVITY
Multiple myeloma (MM) is a plasma cell neoplasm that accounts for approximately 12% of all hematologic cancer and carries one of the worst ratios of death to new cases. It is characterized by the production of monoclonal protein (M-protein) in the blood, and upon development and proliferation in the marrow, the disease often invades adjacent skeletal structures, resulting in the clinical presentation of bone pain. Patients with smoldering (asymptomatic) or Stage I active myeloma may be observed without active therapy because these presentations often follow an indolent course for many years, although this paradigm may be changing for patients considered to be at high risk. On the other hand, the disease course of advanced myeloma is uniformly aggressive, but the introduction of new agents with significant activity has improved outcomes and allowed patients longer periods of remission. Both novel proteasome inhibitors and immunomodulatory agents have effectively transformed the care of patients with newly diagnosed and relapsed/refractory MM, and the emergence of a number of recently approved novel agents with unique mechanisms of action or delivery will likely continue to rapidly alter standard treatment algorithms.
In order to offer optimal patient care, including the option of clinical trial participation, the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME program is designed to assist medical oncologists with the formulation of up-to-date clinical management strategies for the care of patients with MM.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and Research To Practice. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
For questions about CME credit, either email firstname.lastname@example.org or call (717) 531-6483 and reference course number G6488-20-T.
CREDIT DESIGNATION STATEMENT
Audio Program: Penn State College of Medicine designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Video Program: Penn State College of Medicine designates this enduring material for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
HOW TO USE THIS CME ACTIVITY
Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/MMUpdate119/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/MMUpdate119/Video.
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/MMUpdate119/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/MMUpdate119.
CONTENT VALIDATION AND DISCLOSURES
It is the policy of Research To Practice and Penn State College of Medicine to ensure balance, independence, objectivity and scientific rigor in all their educational programs. All faculty, planners and managers participating in this activity are required to disclose any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interest. Research To Practice and Penn State College of Medicine ensured that any conflicts of interest were resolved before the educational activity occurred.
FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
S Vincent Rajkumar, MD
Edward W and Betty Knight Scripps Professor of Medicine
No relevant conflicts of interest to disclose.
Paul G Richardson, MD
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Department of Medical Oncology
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Advisory Committee: Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Oncopeptides, Takeda Oncology; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Oncopeptides, Takeda Oncology.
Nina Shah, MD
Associate Professor of Medicine
University of California, San Francisco
Division of Hematology-Oncology
San Francisco, California
Advisory Committee: Amgen Inc, Genentech, GlaxoSmithKline, Indapta Therapeutics, Karyopharm Therapeutics, Nektar, Oncopeptides, Precision Biosciences, Sanofi Genzyme, Seattle Genetics, Surface Oncology; Contracted Research: bluebird bio, Celgene Corporation, Janssen Biotech Inc, Sutro Biopharma Inc; Data and Safety Monitoring Board: Janssen Biotech Inc; Ownership Interest: Indapta Therapeutics.
Irene M Ghobrial, MD
Professor of Medicine
Director, Clinical Investigator Research Program
Director, Michele and Stephen Kirsch Laboratory
Harvard Medical School
Dana-Farber Cancer Institute
Advisory Committee and Consulting Agreements: Adaptive Biotechnologies, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, NOXXON Pharma, Sanofi Genzyme, Takeda Oncology.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
PENN STATE COLLEGE OF MEDICINE — Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice and Penn State College of Medicine do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Celgene Corporation, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Oncopeptides and Takeda Oncology.
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Release date: September 2019
Expiration date: September 2020
After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.